The development and validation of non-invasive fibrosis tests (NITs) has changed clinical
practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease …

Alcohol consumption is a global phenomenon and a major contributor to alcohol-associated
liver disease (ALD). Detecting individuals at risk of ALD has been challenging, with only a …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Diabetes is a chronic disease characterized by increased blood sugar levels that affects
patient health and life. Following cardiovascular diseases and cancers, it has become the …

Since 1980, the cumulative effort of scientists and health-care stakeholders has advanced
the prerequisites to address metabolic dysfunction-associated steatotic liver disease …

Metabolic-dysfunction associated steatotic liver disease (MASLD), previously known as non-
alcoholic fatty liver disease (NAFLD), is increasingly recognized as a prevalent global …

Although non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis are
increasingly recognised globally, 1 these terms were updated in June 2023 by an …

Background Luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, potentially exerts
pleiotropic effects on the liver. However, the sufficient evidence is still lacking. We aimed to …

Background: Virtually the entire spectrum of liver disease is observed in association with
type 2 diabetes mellitus (T2DM); indeed, T2DM is now the most common cause of liver …

Introduction High prevalence and harmful consequences of hazardous drinking among
medical-surgical patients underscore the importance of intervening with drinking to improve …